Lenti-CEA CAR (scFv-b2cζ, BW431/26)-VP(VP-CAR-LC154)
The ready-to-use lentiviral particles of Lenti-CEA CAR (scFv-b2cζ, BW431/26)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (BW431/26)-b2c-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.
Specifications
Type of Therapeutics
Chimeric Antigen Receptor
Expression Cassette
scFv (BW431/26)-b2c-CD3ζ
Packaging System
Lentivirus
Targeting Diseases
Colon carcinoma
Target
Introduction
Members of the CEACAM subfamily, including CEACAM5, belong to the CEA gene family. For general information on the CEA gene family, see CEACAM1 (MIM 109770).[supplied by OMIM, Oct 2009]
Alternative Names
CEACAM5; carcinoembryonic antigen-related cell adhesion molecule 5; CEA; CD66e; renal cell carcinoma; RCC; renal cell carcinoma; scFv; FcεRIγ; Chimeric antigen receptor; T cell; Retrovirus; CARs; Lentivirus; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; BW431/26
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Related Products
| Cat# |
Description |
| CAR-LC019 |
Anti-CEA h(CD28-CD3ζ) CAR, pCDCAR1 |
| CAR-T-1-M314-2 |
Anti-CEA scFv h(CD28) CART, pCDCAR1 |
| CAR-MZ170 |
Anti-CEA (C2-45) h(CD3ζ) CAR, pCDCAR1 |
| CAR-T-2-M314-2G |
Anti-CEA scFv h(CD28-FcεRIγ) CART, pCDCAR1 |
| CAR-T-1-M314-G |
Anti-CEA scFv h(FcεRIγ) CART, pCDCAR1 |
| CAR-T-2-M314-BZ |
Anti-CEA scFv h(41BB-CD3ζ) CART, pCDCAR1 |
| VP-CAR-LC843 |
Lenti-CEA CAR (scFv-CD28-41BB-CD3ζ, F11-39) Viral Particle |
| CAR-MZ172 |
Anti-CEA (C2-45) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 |
| TCR-L010 |
Mouse anti-CEACAM5 (IMIGVLVGV) T Cell Receptor, pLXSN |
| CAR-MZ105 |
Anti-CEA (MFE23) h(CD3ζ) CAR, pCDCAR1 |
CarcinomaOthers
Kits for CARs/TCRs Development 
Datasheet
Subscribe to Our Newsletter for Updates: